[A case of therapy-related acute monocytic leukemia following low-dose of etoposide treatment for hemophagocytic lymphohistiocytosis].
We report a case of therapy-related acute myeloid leukemia after low-dosed topoisomerase II inhibitor (etoposide) treatment for hemophagocytic lymphohistiocytosis (HLH). A 62-yr-old female patient had previously been treated with a HLH-94 protocol containing a low-dose of etoposide (total dose of 300 mg/m2). Thirty-one months later, the patient was admitted to the hematology department with general weakness and upper respiratory infection symptoms. Peripheral blood smear and bone marrow study revealed acute monocytic leukemia. There was no evidence of myelodysplastic syndrome, and a cytogenetic study showed no chromosomal abnormalities.
Seo
Young Ik
YI
Department of Laboratory Medicine, Soonchunhyang University Hospital, Seoul, Korea.
Park
Rojin
R
Choi
Tae Youn
TY
Shin
Jeung Won
JW
Won
Jong Ho
JH
Park
Hee Sook
HS
Lee
Nam Soo
NS
Cho
Duck
D
D001853:Bone Marrow / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000139:chemically induced* / Q000175:diagnosis* / Q000628:therapy; D051359:Lymphohistiocytosis, Hemophagocytic / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged
D005047:Etoposide